Clarus Therapeutics Holdings
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Cash used in financing activities reached the amount of $62,993,000 last year. Net change in cash is therefore $19,182,000.
Cash Flow
| 2021 | -43.78M | -25K | 62.99M |
|---|
CRXT Cash Flow Statement (2021 – 2021)
| 2021 | |
|---|---|
Cash at beginning of period | 7.23M |
Operating activities | |
Net income | -40.61M |
| Adjustments to reconcile net income to cash generated by operating activities: | |
Depreciation and amortization | 25K |
Stock-based compensation expense | 668K |
| Deferred income tax benefit | 668K |
| Changes in operating assets and liabilities: | |
Accounts receivable, net | -1.94M |
Inventories | -8.35M |
Accounts payable | 1.83M |
Cash generated by operating activities | -43.78M |
Investing activities | |
Purchases Of Investments | 0 |
Investments In Property Plant And Equipment | -25K |
Acquisitions Net | 0 |
Cash generated by investing activities | -25K |
Financing activities | |
Common Stock Issued | 13.80M |
Payments for dividends | -7.73M |
Repurchases of common stock | 0 |
Repayments of term debt | 0 |
Cash used in financing activities | 62.99M |
Net Change In Cash | 19.18M |
Cash at end of period | 26.41M |
| Data source |